Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX004 (Coramitug) in hATTR Amyloidosis
NCT03336580Phase 1Terminated
- Sponsor
- Prothena Corporation
- Start
- Apr 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of coramitug in hereditary transthyretin amyloidosis (hATTR), sponsored by Prothena Corporation. Primary endpoints: Maximum Tolerated Dose at 28 days and Treatment-Emergent Adverse Events at 3 months. Started Apr 2018; status: terminated.
02
Drugs
coramitug
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on NCT03336580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03336580.